Edwards Lifesciences Corporation $EW Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp has reduced its stake in Edwards Lifesciences Corporation by 4.0%, now owning 6,248,217 shares worth approximately $452.87 million.
• Several institutional investors, including First Trust Advisors LP and GeoWealth Management LLC, have significantly increased their investments in Edwards Lifesciences during the fourth quarter.
• Analysts have a consensus rating of "Moderate Buy" for Edwards Lifesciences, with a price target averaging $85.90 per share and recent earnings exceeding expectations.

Northern Trust Corp decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 4.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,248,217 shares of the medical research company's stock after selling 257,010 shares during the period. Northern Trust Corp owned about 1.07% of Edwards Lifesciences worth $452,871,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $27,000. SouthState Corp acquired a new position in Edwards Lifesciences during the first quarter worth about $27,000. Global X Japan Co. Ltd. raised its position in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. Tradewinds Capital Management LLC raised its position in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares during the last quarter. Finally, Rossby Financial LCC acquired a new position in Edwards Lifesciences during the first quarter worth about $29,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.1%

NYSE EW traded down $0.0490 during trading hours on Monday, hitting $81.7810. 643,171 shares of the company's stock were exchanged, compared to its average volume of 4,494,335. The business's 50 day moving average is $77.58 and its 200-day moving average is $74.72. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The firm has a market capitalization of $48.01 billion, a P/E ratio of 11.76, a price-to-earnings-growth ratio of 3.95 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president owned 50,356 shares of the company's stock, valued at $3,897,554.40. This represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,584 shares of company stock worth $1,897,762. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

EW has been the subject of a number of research reports. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Deutsche Bank Aktiengesellschaft upped their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Truist Financial upped their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research report on Friday, July 25th. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Finally, Robert W. Baird upped their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.